NCT02317315

Brief Summary

Preterm delivery (PTD) is a leading cause of neonatal mortality and continues to be a major public health concern, reaching 12.9% in 2006, despite intense research to reverse this trend. Currently, fetal fibronectin (fFN) screening and cervical length determined by ultrasound are two tests which are proven to have benefit in the identification of those at greatest risk for preterm delivery. However the benefit of these tests is limited to situations where a negative result can avoid unnecessary interventions. Currently, maternal fetal monitoring is limited, as it is difficult to "see" what is going on in the placenta (maternal-fetal interface) without invasive measures such as placental biopsy or amniocentesis. Our goal for this study is to identify a group of biomarkers in non-invasive compartments (such as saliva, blood, urine, and/or cervical and vaginal secretions) that are associated with preterm labor and birth. We hypothesize that preterm labor will display an inflammatory profile, which consists of unique inflammatory biomarkers from different non-invasive bodily fluid compartments (such as Il-10 in urine, VEGF in cervical secretions, and IP-10 in saliva), that correlates with a high incidence of preterm birth.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2013

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2013

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

December 10, 2014

Completed
6 days until next milestone

First Posted

Study publicly available on registry

December 16, 2014

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 2, 2016

Completed
1.7 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 7, 2017

Completed
Last Updated

January 29, 2018

Status Verified

January 1, 2018

Enrollment Period

3 years

First QC Date

December 10, 2014

Last Update Submit

January 25, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Gestational age at delivery

    Within 5 months of Preterm labor

Study Arms (1)

Preterm labor group

Patients who are admitted for evaluation of preterm labor.

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Pregnant females between the age of 18-40 who present in preterm labor will be asked to participate.

You may qualify if:

  • Pregnant women age 18-40 years old between 20 to 32 weeks gestation with singleton pregnancies and are admitted to Winthrop University Hospital for evaluation of preterm labor. Preterm labor will be defined as contractions every 5 minutes associated with cervical changes or cervical dilatation \> 2cm with 80% effacement. Subjects must have reliable dates confirmed by early ultrasound.

You may not qualify if:

  • Indicated preterm births (i.e. pre-eclampsia), multiple pregnancies, known major fetal abnormality (ex. those that are known to be incompatible with life) and premature rupture of membranes.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Winthrop University Hosptial

Mineola, New York, 11501, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

1. Saliva - We will collect saliva in a sterile container. 2. Maternal Blood - Blood samples will be collected during routine blood draws and into serum separator tubes, spun, and the serum stored at -80°C. 3. Urine - Urine samples will be collected into a sterile container. 4. Cervical and vaginal secretions - During speculum exam, we will simultaneously insert two Weck-Cell Sponges directly into the cervical os for collection of cervical secretions then another two sponges will be applied in the posterior fornix for collection of vaginal fluid.

MeSH Terms

Conditions

Obstetric Labor, PrematurePremature Birth

Condition Hierarchy (Ancestors)

Obstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Officials

  • RANJITH KAMITY, MD

    Winthrop University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 10, 2014

First Posted

December 16, 2014

Study Start

January 1, 2013

Primary Completion

January 2, 2016

Study Completion

September 7, 2017

Last Updated

January 29, 2018

Record last verified: 2018-01

Locations